SCHEMBL19987607

SCHEMBL19987607

C=C=NCc1ccc(C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.41
C3AR1 Q16581 1/20 0.40
MIF P14174 4/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
TRPA1 O75762 2/20 0.38
AGXT P21549 2/20 0.37
ACHE P22303 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
PYCR1 P32322 1/20 0.34
CTBP2 P56545 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12885577 0.94 C3AR1 (0.37) IDO1C3AR1MIFCYP1A2CYP2A6
SCHEMBL19130299 0.82 CYP2A6 (0.41) MIFCYP2A6TAAR1TRPA1TDP1
SCHEMBL28396661 0.81 IDO1 (0.44) IDO1C3AR1MIFCYP1A2CYP2A6
SCHEMBL436823 0.79 IDO1 (0.42) IDO1C3AR1MIFCYP1A2CYP2A6
SCHEMBL1706732 0.77 MIF (0.63) IDO1C3AR1MIFCYP1A2CYP2A6
SCHEMBL14925996 0.77 TAAR1 (0.38) IDO1MIFCYP2A6TAAR1TRPA1
SCHEMBL6549156 0.76 MIF (0.60) IDO1MIFCYP2A6TRPA1ALDH1A1
SCHEMBL260523 0.74 IDO1 (0.38) IDO1C3AR1MIFCYP1A2CYP2A6
SCHEMBL14926004 0.74 ALDH1A1 (0.47) IDO1MIFCYP1A2TAAR1TRPA1
SCHEMBL12228503 0.73 IDO1 (0.46) IDO1C3AR1CYP1A2CYP2A6TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018078149-A1 NOVEL CYCLICSULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2018-05-03 WO disclosed
WO-2018050571-A1 COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR F. HOFFMANN-LA ROCHE AG (CH) 2018-03-22 WO disclosed